Search Tag: patient outcomes

2024 03 Dec

  According to a new study led by researchers from Weill Cornell Medicine, NewYork-Presbyterian, Yale School of Medicine, and other institutions, tirzepatide, an injectable weight-loss drug marketed as Zepbound, has been shown to reduce the risk of developing type 2 diabetes in patients with obesity and prediabetes by over 90% compared to placebo...Read more

2017 08 May

A randomised trial has just been completed in which patients with heart failure with preserved ejection fraction (HFpEF) were treated with Ivabradine. Currently, there is no known effective treatment for reducing morbidity and mortaility in patients suffering from HFpEF. See Also : Azithromycin Not Linked to Increased Arrhythmia Risk HFpEF...Read more